Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Sci Rep ; 3: 3113, 2013 Nov 01.
Artículo en Inglés | MEDLINE | ID: mdl-24177907

RESUMEN

Omega-3 polyunsaturated fatty acids such as eicosapentaenoic acid (EPA) have anti-inflammatory effects. Preterm birth is an important problem in modern obstetrics and one of the main causes is an inflammation. We here showed that abundance of omega-3 fatty acids reduced the incidence of preterm birth induced by LPS with fat-1 mice, capable of converting omega-6 to omega-3 fatty acids. We also indicated that the gene expression of IL-6 and IL-1ß in uteruses and the number of cervical infiltrating macrophages were reduced in fat-1 mice. The analyses of lipid metabolomics showed the high level of 18-hydroxyeicosapentaenoate in fat-1 mice, which was derived from EPA and was metabolized to anti-inflammatory product named resolvin E3 (RvE3). We finally showed that the administration of RvE3 to LPS-exposed pregnant wild type mice lowered the incidence of preterm birth. Our data suggest that RvE3 could be a potential new therapeutic for the prevention of preterm birth.


Asunto(s)
Ácidos Grasos Omega-3/metabolismo , Nacimiento Prematuro/metabolismo , Nacimiento Prematuro/prevención & control , Animales , Citocinas/metabolismo , Ácidos Grasos Insaturados/administración & dosificación , Femenino , Incidencia , Mediadores de Inflamación/metabolismo , Metabolismo de los Lípidos , Macrófagos/metabolismo , Macrófagos/patología , Ratones , Modelos Animales , Miometrio/metabolismo , Miometrio/patología , Embarazo , Nacimiento Prematuro/epidemiología , Nacimiento Prematuro/etiología
2.
PLoS One ; 8(9): e73085, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-24039864

RESUMEN

Omega-3 polyunsaturated fatty acids (omega-3 PUFAs) play a role in controlling pathological inflammatory reactions. Endometriosis is characterized by the presence of endometrial tissue on the peritoneum and an exaggerated inflammatory environment around ectopic tissues. Here peritoneal endometriosis was reproduced using a mouse model in which murine endometrial fragments were inoculated into the peritoneal cavity of mice. Fat-1 mice, in which omega-6 can be converted to omega-3 PUFAs, or wild type mice, in which it cannot, were used for the endometriosis model to address the actions of omega-3 PUFAs on the development of endometriotic lesions. The number and weight of cystic endometriotic lesions in fat-1 mice two weeks after inoculation were significantly less than half to those of controls. Mediator lipidomics revealed that cystic endometriotic lesions and peritoneal fluids were abundant in 12/15-hydroxyeicosapentaenoic acid (12/15-HEPE), derived from eicosapentaenoic acid (EPA), and their amount in fat-1 mice was significantly larger than that in controls. 12/15-Lipoxygenase (12/15-LOX)-knockout (KO) and control mice with or without EPA administration were assessed for the endometriosis model. EPA administration decreased the number of lesions in controls but not in 12/15-LOX-KO mice. The peritoneal fluids in EPA-fed 12/15-LOX-KO mice contained reduced levels of EPA metabolites such as 12/15-HEPE and EPA-derived resolvin E3 even after EPA administration. cDNA microarrays of endometriotic lesions revealed that Interleukin-6 (IL-6) expression in fat-1 mice was significantly lower than that in controls. These results suggest that both endogenous and exogenous EPA-derived PUFAs protect against the development of endometriosis through their anti-inflammatory effects and, in particular, the 12/15-LOX-pathway products of EPA may be key mediators to suppress endometriosis.


Asunto(s)
Endometriosis/metabolismo , Endometriosis/patología , Ácidos Grasos Omega-3/metabolismo , Enfermedades Peritoneales/metabolismo , Enfermedades Peritoneales/patología , Animales , Araquidonato 12-Lipooxigenasa/genética , Araquidonato 12-Lipooxigenasa/metabolismo , Araquidonato 15-Lipooxigenasa/genética , Araquidonato 15-Lipooxigenasa/metabolismo , Modelos Animales de Enfermedad , Endometriosis/genética , Femenino , Perfilación de la Expresión Génica , Interleucina-6/genética , Interleucina-6/metabolismo , Metabolismo de los Lípidos , Macrófagos/metabolismo , Ratones , Ratones Transgénicos , ARN Mensajero/genética , ARN Mensajero/metabolismo
3.
Fertil Steril ; 94(6): 2455-7, 2010 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-20334863

RESUMEN

We demonstrated that cholesterol sulfate (CS) inhibits invasion of a trophoblast cell line and plasmin enzyme activity in a noncompetitive manner by binding to the enzyme itself, suggesting that CS can repress cell invasion by inhibiting proteinases such as those involved in the plasminogen activator/plasmin system. Considering these results, it is possible that CS may act as a signaling molecule between the trophoblast and endometrium, and may regulate the process of implantation.


Asunto(s)
Movimiento Celular/efectos de los fármacos , Ésteres del Colesterol/farmacología , Péptido Hidrolasas/metabolismo , Trofoblastos/efectos de los fármacos , Adhesión Celular/efectos de los fármacos , Línea Celular Tumoral , Relación Dosis-Respuesta a Droga , Regulación hacia Abajo , Evaluación Preclínica de Medicamentos , Activación Enzimática/efectos de los fármacos , Humanos , Inhibidores de Proteasas/farmacología , Factores de Tiempo , Trofoblastos/metabolismo , Trofoblastos/fisiología
4.
Int J Oncol ; 32(3): 593-601, 2008 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-18292936

RESUMEN

The expression of growth hormone-releasing hormone (GHRH) and its receptors has been demonstrated in peripheral tissues as well as CNS. Recently, the functional splice variant SV1 of GHRH receptor was identified in various human cancers and cancer cell lines. Although antineoplastic activity of GHRH antagonists has been clearly demonstrated, the mechanism of action is incompletely understood. The objective of this study was the investigation of direct anti-proliferative effect of GHRH antagonist MZ-5-156 on HEC-1A human endometrial cancer cell line and the elucidation of underlying mechanisms. RT-PCR revealed the expression of mRNA for GHRH and SV1 of GHRH receptor in HEC-1A cells. MZ-5-156, at concentrations between 10(-7) and 10(-5) M, had a dose-dependent antiproliferative effect on HEC-1A cells, as determined by 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, (MTS) assay. Hoechst 33342 staining and flow cytometric analysis indicated that MZ-5-156, at 10(-6) M, induced apoptosis in HEC-1A cells after 48 h of treatment. Western blot analysis of apoptosis-related proteins demonstrated that treatment with MZ-5-156 (10(-6) M) for 48 h significantly increased the protein levels of Fas, phospho-p53 (Ser46), p53AIP1 (p53-regulated Apoptosis-Inducing Protein 1), and caspase-8, -9, and -3, and decreased the protein level of Bcl-2. These results demonstrate that MZ-5-156 can directly inhibit the proliferation of human endometrial cancer cells, which express mRNA for GHRH and SV1 of GHRH receptor, presumably through the induction of p53-dependent apoptosis coupled with the up-regulation of Fas, phospho-p53 (Ser46), p53AIP1, and caspase-8, -9, and -3, and the down-regulation of Bcl-2.


Asunto(s)
Adenocarcinoma Papilar/patología , Proliferación Celular/efectos de los fármacos , Neoplasias Endometriales/patología , Hormona Liberadora de Hormona del Crecimiento/antagonistas & inhibidores , Sermorelina/análogos & derivados , Adenocarcinoma Papilar/genética , Anciano , Antineoplásicos/farmacología , Apoptosis/efectos de los fármacos , Apoptosis/genética , Caspasas/genética , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Evaluación Preclínica de Medicamentos , Neoplasias Endometriales/genética , Femenino , Regulación Neoplásica de la Expresión Génica , Genes bcl-2 , Genes p53 , Hormona Liberadora de Hormona del Crecimiento/genética , Humanos , ARN Mensajero/metabolismo , Receptores de Neuropéptido/genética , Receptores de Neuropéptido/metabolismo , Receptores de Hormona Reguladora de Hormona Hipofisaria/genética , Receptores de Hormona Reguladora de Hormona Hipofisaria/metabolismo , Sermorelina/farmacología , Transducción de Señal/efectos de los fármacos , Transducción de Señal/genética
5.
Fertil Steril ; 89(5 Suppl): 1344-7, 2008 May.
Artículo en Inglés | MEDLINE | ID: mdl-17511992

RESUMEN

OBJECTIVE: To investigate the effect of dienogest on the proliferation of endometriotic stromal cells. DESIGN: Comparative and laboratory study. SETTING: University of Tokyo Hospital. PATIENT(S): Endometriotic stromal cells were isolated and cultured from ovarian endometriomas of patients undergoing surgery. INTERVENTION(S): Dienogest was added to the cultured endometriotic stromal cells. MAIN OUTCOME MEASURE(S): 5-Bromo-2'-deoxyuridine (BrdU) incorporation into DNA of the endometriotic stromal cells was measured by ELISA. Cell cycle analysis of the cultured endometriotic stromal cells was performed by flow cytometry. RESULT(S): Dienogest at concentration of 10(-7) M and 10(-6) M significantly inhibited BrdU incorporation into DNA at 24 and 48 hours. Dienogest significantly increased the cells in G0/G1 phase and reduced the cells in S phase and G2/M phase in 24 and 48 hours. CONCLUSION(S): The present study indicates that dienogest can inhibit the proliferation of the endometriotic stromal cells with G0/G1 arrest, suggesting a possible direct effect of dienogest in the treatment of endometriosis.


Asunto(s)
Bromodesoxiuridina/farmacocinética , Proliferación Celular/efectos de los fármacos , Endometriosis/patología , Fase G1/efectos de los fármacos , Nandrolona/análogos & derivados , Enfermedades del Ovario/patología , Fase de Descanso del Ciclo Celular/efectos de los fármacos , Células del Estroma/patología , Adulto , Ciclo Celular/efectos de los fármacos , Células Cultivadas , Anticonceptivos Orales/farmacología , ADN/metabolismo , Evaluación Preclínica de Medicamentos , Endometriosis/metabolismo , Femenino , Humanos , Nandrolona/farmacología , Enfermedades del Ovario/metabolismo , Células del Estroma/metabolismo
6.
Am J Reprod Immunol ; 57(4): 287-93, 2007 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-17362390

RESUMEN

PROBLEM: To get insight into the basis for the empirical usage of herbal medicines, such as Tokishakuyaku-san (Toki) and Sairei-to (Sai) in the treatment of recurrent abortion and intrauterine growth restriction, we examined whether these medicines modulate the production of granulocyte-macrophage colony-stimulating factor (GM-CSF), a cytokine working as an important mediator for intercellular communication in the embryonic development, in decidual stromal cells (DSCs). METHOD OF STUDY: Human DSCs were cultured with either Toki or Sai at several different concentrations. The effect on cell proliferation was assessed by WST-8 assay. GM-CSF released into culture medium was analyzed using enzyme-linked immunosorbent assay, and semi-quantitative polymerase chain reaction was carried out to see GM-CSF mRNA expression in DSCs. RESULTS: Sai inhibited the proliferation of cultured DSCs, while no interference was observed in the presence of Toki. Both Toki and Sai enhanced the release of GM-CSF into culture medium. The amount of GM-CSF mRNA in cultured DSCs was as well increased by either Toki or Sai. CONCLUSION: Considering the significance of GM-CSF in embryonic development, clinical benefit of these herbal medicines in the treatment of recurrent abortion might be based on the shown pharmacological reaction related to GM-CSF.


Asunto(s)
Aborto Habitual/prevención & control , Decidua/efectos de los fármacos , Medicamentos Herbarios Chinos/farmacología , Factor Estimulante de Colonias de Granulocitos y Macrófagos/efectos de los fármacos , Células del Estroma/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Células Cultivadas , Decidua/metabolismo , Ensayo de Inmunoadsorción Enzimática , Femenino , Factor Estimulante de Colonias de Granulocitos y Macrófagos/biosíntesis , Humanos , Embarazo , ARN Mensajero/análisis , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Células del Estroma/metabolismo
7.
Neurosci Res ; 57(4): 504-12, 2007 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-17250915

RESUMEN

Near-infrared spectroscopy (NIRS) has the potential for clinical application in neuropsychiatry because it enables non-invasive and convenient measurement of hemodynamic response to cognitive activation. Using 24-channel NIRS in 12 healthy men, we examined the replicability of oxy- and deoxy-hemoglobin concentration ([oxyHb], [deoxyHb]) changes in the prefrontal cortex during the category fluency task over four repeated sessions (each 1-week apart). Multiple methods were employed to evaluate the replicability of magnitude, location, and time course of the NIRS signals ([oxyHb], [deoxyHb]). Task performances did not differ significantly across sessions, nor were they significantly correlated with NIRS signals. Repeated measures ANOVA and variance component analysis indicated high replicability of magnitude for both NIRS measures, whereas the effect sizes of between-session differences in [oxyHb] were not negligible. The number and spatial location of significantly activated channels were sufficiently replicable for both measures, except that the across-session overlap of significantly activated channels was weak in [deoxyHb]. The time course of the activation was acceptably replicable in both measures. Taken together, these findings suggest there is considerable replicability of multiple-time measurements of prefrontal hemodynamics during cognitive activation in men. Further studies using different conditions or assessing sensitivity to longitudinal changes following interventions are necessary.


Asunto(s)
Mapeo Encefálico , Corteza Prefrontal/fisiología , Espectroscopía Infrarroja Corta , Conducta Verbal/fisiología , Estimulación Acústica/métodos , Adulto , Análisis de Varianza , Circulación Cerebrovascular , Hemoglobinas/metabolismo , Humanos , Masculino , Pruebas Neuropsicológicas , Oxihemoglobinas/metabolismo , Reproducibilidad de los Resultados , Factores de Tiempo
8.
Transfus Apher Sci ; 31(1): 21-8, 2004 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-15294191

RESUMEN

The objective of this study was to establish a novel method of preoperative autologous blood donation (PAD) for surgery of gynecologic malignancies, which requires considerable amounts of plasma relative to the red blood cell component. To collect a double volume of plasma over the amount obtained from whole blood without using an aphaeresis system, we first collected 500 ml of whole blood (2.5 units), and centrifuged it. We gave back the resultant red cell component alone, and retained the plasma component. We further collected an additional 500 ml of whole blood, and centrifuged it. The red cell component (2.5 units) was stored in the refrigerator (as a concentrated red cell, CRC). The resultant plasma together with the plasma collected first (5 units) was frozen and stored in the freezer (fresh frozen plasma, FFP), We repeated this procedure at most three times at intervals of 1 week. Erythropoietin was injected once a week and iron tablets were prescribed. Ninety-nine patients undergoing surgery for a gynecological malignancy were subjected to this method and 86 patients without PAD served as a control. We conducted the procedure for PAD without any noticeable side effects. The amount of actual use of allogeneic CRC and FFP were significantly reduced in the PAD group compared with the control group. In particular, 93.6% of the PAD cases who gave 10 or less units of FFP could go without allogeneic FFP. Postoperative serum albumin levels were higher in the PAD group compared with the control. We have established a novel PAD method which can yield a greater volume of FFP relative to CRC, thus meeting requirements for surgery for gynecological malignancies.


Asunto(s)
Transfusión de Sangre Autóloga/métodos , Neoplasias de los Genitales Femeninos/cirugía , Pérdida de Sangre Quirúrgica , Recolección de Muestras de Sangre/métodos , Epoetina alfa , Eritropoyetina/uso terapéutico , Femenino , Neoplasias de los Genitales Femeninos/sangre , Hematínicos/uso terapéutico , Hemoglobinas/análisis , Humanos , Selección de Paciente , Volumen Plasmático , Cuidados Preoperatorios , Proteínas Recombinantes
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA